No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Samsung Bioepis Initiates Phase I Trial for Pembrolizumab Biosimilar (SB27)
Samsung Bioepis announced that it has commenced a Ph 1 clinical trial for SB27, biosimilar to Merck’s Keytruda® (pembrolizumab). The study will compare the pharmacokinetics, efficacy, safety, and immunogenicity of SB27 with EU and US-sourced Keytruda®, in patients...